Ms Helen Feilden
Hub Project Manager
Continuous Manufacturing And Crystallisation
Back to staff profile
Publications
- Digital process design to define and deliver pharmaceutical particle attributes
- Urwin Stephanie J, Chong Magdalene WS, Li Wei, McGinty John, Mehta Bhavik, Ottoboni Sara, Pathan Momina, Prasad Elke, Robertson Murray, McGowan Mark, al-Attili Mais, Gramadnikova Ekaterina, Siddique Mariam, Houson Ian, Feilden Helen, Benyahia Brahim, Brown Cameron J, Halbert Gavin W, Johnston Blair, Nordon Alison, Price Chris J, Reilly Chris D, Sefcik Jan, Florence Alastair J
- Chemical Engineering Research and Design Vol 196, pp. 726-749 (2023)
- https://doi.org/10.1016/j.cherd.2023.07.003
- The CMAC quality by digital design workflow
- Mustoe Chantal, Brown Cameron, Markl Daniel, Houson Ian, Feilden Helen, Robertson Murray, Florence Alastair
- CMAC Annual Open Day 2022, pp. 65-65 (2022)
- The CMAC MicroFactory : mefenamic acid
- Chong Magdalene, Brown Cameron, Mustoe Chantal, McGinty John, Li Wei, Pathan Momina, Ottoboni Sara, Prasad Elke, Robertson Murray, Mehta Bhavik, McGowan Mark, Siddique Humera, Raval Vishal, Pereira Diaz Laura, Siddique Mariam, Eales William, Turner Alice, Johnston Blair, Robertson John, Halbert Gavin, Price Chris, Benyahia Brahim, Rielly Chris, Sefcik Jan, Nordon Alison, McGlone Thomas, Smith Kenneth, Feilden Helen, Houson Ian, Florence Alastair
- CMAC Annual Open Day 2022, pp. 62-62 (2022)
Back to staff profile
Projects
- Alignment Of Synthesis, Medicinal Chemistry And Strucrural Genomics To Accelerate Uk Drug Discovery: Network SMS-Drug
- Tomkinson, Nick (Principal Investigator) C. Bagley, Mark (Academic) Feilden, Helen (Academic) Johnston, Blair (Academic) Knapp, Stefan (Academic) MacKay, Simon (Academic) Overington, John (Academic) Spencer, John (Academic)
- "This programme will establish an Academia-Users Network in Chemical Biology to initiate, establish and nurture collaborative projects for the advancement of the drug discovery process. It aims to expand the capability of UK drug discovery, with new drug targets, new tools to validate targets and new multidisciplinary partnerships to explore the platforms, tools and targets of the future.
In the post-genomic age opportunities for the development of new clinically validated targets for drug discovery and ultimately medicines are considerable. Drug discovery resources in academia and industry are not used efficiently, to the detriment of industry and society. Duplication could be reduced, and productivity could be increased, by performing basic biology and clinical proofs of concept within open access industry-academia partnerships.
The major obstacle to clinical validation of new drug targets and the invention of new medicines is the availability and efficient delivery of small-molecules probes in order to understand the basic biology. Provision of these probes will allow for pre-clinical validation of drug targets and reduce the duplication of efforts across the pharmaceutical industry. Failures of potential drug molecules in late stage clinical trials result in enormous cost to the companies involved, the pharmaceutical industry in general and also dashes the hopes of countless patients.
A relatively poor understanding of disease mechanisms, particularly in humans, confounds the drug discovery process and represents a pivotal area of biological research. Potent, selective and cell-permeable chemical probes are valued reagents in both fundamental and applied biological research, and they are essential for preclinical target validation in academic and industrial laboratories.
Strategic alignment of academic synthetic chemists, molecular modellers and structural biologists with industrial end users will provide a blueprint for the provision of open access chemical probes to support clinical validation and drug discovery efforts within the UK." - 01-Jan-2011 - 31-Jan-2015
Back to staff profile
Contact
Ms
Helen
Feilden
Hub Project Manager
Continuous Manufacturing And Crystallisation
Email: helen.feilden@strath.ac.uk
Tel: 444 7127